Core Viewpoint - The Hong Kong International Biotechnology Forum and Exhibition (BIOHK) 2025 serves as a significant platform for industry leaders to discuss the future of biotechnology, with a focus on the global strategy of the pharmaceutical company YuanDa Pharmaceutical [1][3]. Group 1: Company Strategy and Globalization - YuanDa Pharmaceutical is recognized as a leading global player in nuclear medicine, sharing its global strategy at the BIOHK 2025 forum [3][6]. - The company is implementing a "Go Global" strategy, focusing on global research, production, and sales to enhance the value of innovative products [3][10]. - YuanDa has achieved significant milestones in its nuclear medicine development, with its product Yttrium-90 microsphere injection being used in over 150,000 patients across more than 50 countries [6][10]. Group 2: Product Development and Market Expansion - The company has received CE mark certification for new indications of its innovative product, expanding its treatment scope to include multiple types of liver cancer, which is expected to double its market potential [6][10]. - YuanDa is advancing its pipeline with 15 innovative products in development, covering various cancers and utilizing five types of radioactive isotopes [7][9]. - The company is actively pursuing a "dual filing" strategy in the U.S. and China, with several products entering international Phase III clinical trials [9][10]. Group 3: Research and Production Capabilities - YuanDa has established a comprehensive global network for nuclear medicine, with research and production bases in Boston and Chengdu, and a sales network covering over 50 countries [11][13]. - The company has built a state-of-the-art production facility in Chengdu, recognized as one of the most automated and comprehensive nuclear medicine factories globally [11][13]. - YuanDa's global innovation strategy includes five research platforms and eight research centers, with a robust pipeline of 133 projects in various stages of development [13].

Core Viewpoint - The Hong Kong International Biotechnology Forum and Exhibition (BIOHK) 2025 serves as a significant platform for industry leaders to discuss the future of biotechnology, with a focus on the global strategy of Yuan Da Pharmaceutical in nuclear medicine [1][3]. Group 1: Company Strategy - Yuan Da Pharmaceutical is recognized as a leading global nuclear medicine company, sharing its unique global development strategy at the forum [3][5]. - The company is implementing a "Go Global" strategy, focusing on global R&D, production, and sales to enhance the long-term value of innovative products [3][5][9]. Group 2: Market Expansion - The recognition of Chinese innovative drugs is increasing globally, with a notable rise in the number of oral presentations by Chinese pharmaceutical companies at the ASCO conference, from 25 in 2023 to 84 in 2025 [3]. - In the first half of 2025, the transaction value of innovative drug licensing exceeded the total for 2024, indicating strong innovation capabilities [3]. Group 3: Product Development - Yuan Da Pharmaceutical has achieved significant breakthroughs in nuclear medicine, with its innovative product, Yttrium-90 microsphere injection, being used in over 50 countries and for more than 150,000 patients [5]. - The product is the first and only FDA-approved treatment for unresectable hepatocellular carcinoma (HCC) and colorectal cancer liver metastases, recently receiving CE mark certification for additional indications [5]. Group 4: R&D Pipeline - The company has 15 innovative products in the R&D registration phase, utilizing five types of radioactive isotopes to target eight different cancers [6][8]. - Yuan Da is advancing its "dual filing" strategy in the U.S. and China, with several products entering international multi-center Phase III clinical trials [8]. Group 5: Global Infrastructure - Yuan Da Pharmaceutical has established a comprehensive global sales network covering over 50 countries, supported by R&D bases in Boston and Chengdu, and production facilities in multiple international locations [10][12]. - The company’s Chengdu facility is noted for being one of the most automated and comprehensive nuclear medicine production plants globally, ensuring high-quality product supply [10]. Group 6: Long-term Vision - The company aims to deepen its global market penetration and brand development through its ongoing "Go Global" strategy, addressing unmet medical needs worldwide [12].

Group 1: Financial Performance - The company reported total revenue of 13.273 billion RMB, a year-on-year decrease of 18.5% [1] - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year, with basic earnings per share at 22.29 cents [1] - The gross profit margin decreased by 6.0 percentage points to 65.6%, primarily due to a reduction in the revenue share from the prescription drug business [1] Group 2: Research and Development - R&D expenses increased by 5.5% year-on-year to 2.683 billion RMB, accounting for 26.2% of prescription drug revenue [1] - The company has nearly 90 products in various stages of clinical trials, with 12 submitted for market approval and over 30 key products in the registration clinical phase [1] - The company focuses on high-demand treatment areas such as breast cancer and lung cancer, accelerating the commercialization of core products [2] Group 3: Strategic Initiatives - The company is implementing a "dual-driven" strategy of "innovation + internationalization," enhancing cooperation with global innovative pharmaceutical companies [2] - Authorization revenue reached 1.075 billion RMB in the first half of 2025, providing new growth momentum for the prescription drug business [2] - The company has completed four external authorization projects with a cumulative contract amount of 9.71 billion USD [3] Group 4: Global Expansion and Recognition - The company has been recognized as a "national-level innovative enterprise" and has established key national laboratories [4] - It ranks 19th in the global TOP25 pipeline scale pharmaceutical companies, improving its position by 5 places compared to the previous year [4] - The company is expected to submit over 50 new drugs or new indications for approval by the end of 2028 [4]

Core Viewpoint - The mid-term performance announcement of Hansoh Pharmaceutical highlights the company's clear innovation transformation and internationalization strategy, with significant growth in revenue and profit driven by innovative drugs and collaborative products [2][3]. Financial Performance - In the first half of 2025, Hansoh Pharmaceutical reported revenue of approximately RMB 74.34 billion, a year-on-year increase of about 14.3%, and a profit of approximately RMB 31.35 billion, up by about 15.0% [2]. - Basic earnings per share reached approximately RMB 0.53, reflecting a year-on-year growth of about 14.8% [2]. Innovation and Product Sales - Sales revenue from innovative drugs and collaborative products amounted to approximately RMB 61.45 billion, marking a year-on-year increase of 22.1% and accounting for about 82.7% of total revenue [2][3]. - The company has seen a significant shift from "generic-innovative combination" to "innovation-driven" strategies, indicating a successful transformation in response to policy guidance and market demand [2][3]. Collaborative Agreements - In the first half of 2025, Hansoh received a BD licensing fee of USD 112 million from Merck, and in June 2025, it granted Regeneron exclusive overseas licensing rights for the GLP-1/GIP dual receptor agonist HS-20094, receiving an upfront payment of USD 80 million [2]. - The company is also engaged in multiple collaborations, including a partnership with Lupo Pharmaceutical for the BTK inhibitor LP-168, which aims to expand its pipeline for autoimmune diseases [6][7]. Research and Development Investment - Hansoh's R&D expenditure reached RMB 14.41 billion in the first half of 2025, representing a year-on-year increase of 20.4% and accounting for 19.4% of total revenue [6]. - The company is pursuing a dual-track strategy of "introduction and output," enhancing its product pipeline and reducing risks associated with single R&D projects [6][10]. Market Position and Industry Trends - The 82.7% share of innovative revenue significantly exceeds the industry average of 50%-70% for leading domestic pharmaceutical companies [3]. - The Chinese innovative drug sector has seen over 50 BD outbound transactions by June 30, 2025, with a total disclosed cooperation amount of USD 48.448 billion, marking a historic high [9]. Strategic Evolution - The industry is shifting from "single transactions" to "ecosystem co-construction," with deeper collaboration across the pharmaceutical value chain, including partnerships with biotech firms and research institutions [10]. - The trend indicates a move towards strategic binding and shared interests among partners, enhancing long-term value and reducing risks associated with new product development [10].